Vitrolife
109.30 SEK
+2.63 %
Less than 1K followers
VITR
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Vitrolife
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 1,480.1 | 1,245.6 | 1,680.8 | 3,234.0 | 3,512.0 | 3,609.0 | 3,440.0 |
| growth-% | -15.8 % | 34.9 % | 92.4 % | 8.6 % | 2.8 % | -4.7 % | |
| EBITDA | 530.2 | 394.6 | 454.1 | 732.0 | -3,404.0 | 962.0 | 949.0 |
| EBIT | 487.9 | 370.0 | 435.4 | 654.0 | -3,589.0 | 783.0 | -4,835.0 |
| Profit before taxes | 492.7 | 366.2 | 460.0 | 537.0 | -3,712.0 | 674.0 | -4,886.0 |
| Net income | 383.8 | 287.9 | 343.6 | 394.0 | -3,851.0 | 514.0 | -5,013.0 |
| EPS | 3.53 | 2.64 | 2.97 | 2.91 | -28.44 | 3.79 | -37.01 |
| Dividend | 1.05 | 0.80 | 0.80 | 0.85 | 1.00 | 1.10 | 1.10 |
| Dividend ratio | 29.8 % | 30.3 % | 26.9 % | 29.2 % | -3.5 % | 29.0 % | -3.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 35.8 % | 31.7 % | 27.0 % | 22.6 % | -96.9 % | 26.7 % | 27.6 % |
| EBIT-% | 33.0 % | 29.7 % | 25.9 % | 20.2 % | -102.2 % | 21.7 % | -140.6 % |
| ROE | 21.4 % | 14.3 % | 2.2 % | 2.4 % | -30.3 % | 3.8 % | -63.5 % |
| ROI | 17.9 % | 12.5 % | 1.8 % | 1.9 % | -23.6 % | 2.9 % | -45.1 % |